PeRx Review

What PeRx charges

• BPC-157: $199/mo — starting at — the pricing page reads "Through PeRx, BPC-157 therapy is available as part of a personalized protocol starting at $199." The same page puts the whole catalog at "$199-$349 per month"

PeRx also sells 13 compounds this site boards without publishing a price for them: TB-500 (board ranks no provider), GHK-Cu, Epitalon (board ranks no provider), NAD+, MOTS-C (board ranks no provider), PT-141, CJC-1295 (board ranks no provider), Ipamorelin (board ranks no provider), Sermorelin, Tesamorelin, Semax (board ranks no provider), Glutathione and KPV (board ranks no provider).

A price that is drawn and then hidden

Each product page renders a per-month figure in a large font directly above a line inviting the reader to create a free account to view pricing. The figure is styled with a heavy blur and marked hidden from assistive technology.

So the number is in the markup, is not readable by eye, and is deliberately withheld from a screen reader. The same value is repeated inside the page's structured data, where no human sees it at all.

This site treats none of that as a published price. A figure a page hides from sighted readers and from assistive technology alike has not been disclosed; it has been teased. Structured data is not publication either, and on this roster a hidden figure and a visible one have already been caught disagreeing.

The practical result for a shopper is that not one of the twenty-six catalog entries carries a readable price of its own.

What the pricing page does publish

A separate pricing page answers the cost question in ordinary body copy. It states a floor for a treatment plan, gives a range across the catalog, and adds that supplies and shipping sit inside the figure.

One compound is named with the floor attached to it in its own answer, which is the single row this site records for this seller. Everything else on the menu is declared here with no figure at all.

The same page carries a comparison table setting its own range against in-clinic pricing and against research-grade material sold for laboratory use. That table is the seller's own characterization of its competitors, not a finding.

The page also contradicts itself. It lists the absence of a separate consultation fee among the things every order includes, then answers twice, further down the same page, that provider consultations carry a fee. The more expensive reading is the one recorded here.

The widest declared menu on this roster, tied

Every compound this site tracks appears in this catalog, which one other seller here also manages. Two of the sixteen come only inside a four-peptide blend that the product page spells out by name.

Four catalog entries are excluded from this row on purpose. Two sublingual weight-loss products are marked as not yet available and two others as unavailable, so none of the four is something this seller sells today.

Breadth is not the same as availability, and it is certainly not the same as evidence. Several of these compounds sit on boards this site withholds entirely, because the regulatory question about them is unsettled.

None of the compounded products here is an FDA-approved finished drug. The product pages say so themselves, and they also note that some of these compounds are prohibited by anti-doping bodies.

Who you are contracting with, and what happens after you pay

The terms open by naming the operating company and the trade name it does business under, which is the clearest answer any document on the site gives about the entity behind the brand.

They also name the outside platform through which the telehealth consultations happen, and say the company is not itself a healthcare provider. The dispensing pharmacy is described only by category and is never named. Ten of the thirty-eight sellers here name the facility that fills an order; this is one of the twenty-eight that do not.

Shipping coverage is stated flatly in the terms as every state, and the pricing page repeats it as a headline statistic. That is recorded as the state footprint on this row.

The refund position is unusually firm: once payment is processed against an approved prescription, the terms say all sales are final and cancellations are not accepted.

How we verified this

• Loaded ten product pages and the pricing page, then re-loaded the pricing page more than a minute later and compared its price text token by token; the two readings were identical.
• Probed the host with a nonsense path at two different path depths in the same run and confirmed a not-found response at each.
• Read the price element's own markup on a product page and found the blur and the hidden-from-assistive-technology attribute, which is why no product-page figure was recorded.
• Checked the page's structured data separately and confirmed it repeats the same hidden figure, then declined to use it, because a value only a machine can read has not been published.
• Took the recorded figure from body copy on the pricing page, where it appears in a sentence naming the compound.
• Recorded the more expensive reading of the consultation fee and named the conflict, rather than choosing the reading that flatters the seller.
• Took the compound list from the catalog's own headings and excluded the four entries the catalog itself marks as unavailable or not yet available.
• Read the blend product page in full to establish which single peptides it contains, rather than inferring them from the blend's name.
• Re-counted the pharmacy-naming claim against the current roster rather than reusing an earlier figure.